RNA Overview

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.

Wall Street analysts forecast RNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNA is75.63 USD with a low forecast of 72.00 USD and a high forecast of 96.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Avidity Biosciences, Inc revenue for the last quarter amounts to 859.00K USD, decreased -71.11

Avidity Biosciences, Inc. EPS for the last quarter amounts to -1.70 USD, increased 153.73

Avidity Biosciences, Inc (RNA) has 47 emplpoyees as of March 11 2026.

Today RNA has the market capitalization of 227.60M USD.